Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

NGNE

Neurogene Inc

May 08 • 04:00PM ET

32.90

Dollar change -1.04
Percentage change -3.06	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI VXF DWAS AVSC DFAS

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.91	Insider Own	10.43%	Shs Outstand	12.82M	Perf Week	-2.58%
Market Cap	423.42M	Forward P/E	-	EPS next Y	-3.62	Insider Trans	0.00%	Shs Float	11.52M	Perf Month	-19.68%
Income	-36.32M	PEG	-	EPS next Q	-1.03	Inst Own	61.84%	Short Float	8.58%	Perf Quarter	8.10%
Sales	0.00M	P/S	-	EPS this Y	-231.74%	Inst Trans	-32.57%	Short Ratio	7.23	Perf Half Y	140.50%
Book/sh	14.51	P/B	2.27	EPS next Y	6.11%	ROA	-21.46%	Short Interest	0.99M	Perf Year	86.93%
Cash/sh	15.32	P/C	2.15	EPS next 5Y	25.10%	ROE	-25.91%	52W Range	12.20 - 53.00	Perf YTD	69.76%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-16.09%	ROI	-18.31%	52W High	-37.92%	Beta	1.38
Dividend TTM	-	Quick Ratio	8.72	Sales past 5Y	-20.00%	Gross Margin	-	52W Low	169.67%	ATR (14)	2.69
Dividend Ex-Date	-	Current Ratio	8.72	EPS Y/Y TTM	-71.39%	Oper. Margin	0.00%	RSI (14)	43.80	Volatility	8.85% 7.44%
Employees	91	Debt/Eq	0.08	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	51.50
Option/Short	No / Yes	LT Debt/Eq	0.07	EPS Q/Q	-283.53%	Payout	-	Rel Volume	0.44	Prev Close	33.94
Sales Surprise	-	EPS Surprise	349.72%	Sales Q/Q	-	Earnings	Mar 18 AMC	Avg Volume	136.59K	Price	32.90
SMA20	-2.86%	SMA50	-13.48%	SMA200	42.32%	Trades		Volume	60,719	Change	-3.06%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-29-24	Initiated	Leerink Partners	Outperform	$46
Mar-21-24	Initiated	William Blair	Outperform	$61
Jan-08-24	Initiated	H.C. Wainwright	Buy	$45
Jan-05-24	Initiated	Stifel	Buy	$31
Jan-04-24	Initiated	TD Cowen	Outperform

May-07-24 06:19AM	Neurogene Presents Favorable Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome during ASGCT Annual Meeting (Business Wire)
Apr-22-24 04:36PM	Neurogene Announces Upcoming Presentation of Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome at ASGCT Meeting (Business Wire)
Mar-20-24 05:31AM	Neurogene Inc (NGNE) Reports Financial Results for Q4 and Full Year 2023 (GuruFocus.com)
Mar-18-24 04:14PM	Neurogene Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Updates (Business Wire)
Mar-04-24 07:30AM	Neurogene Announces Expansion and Plans for More Rapid Patient Enrollment of Rett Syndrome Gene Therapy Clinical Trial (Business Wire) +20.47%
07:30AM	Loading…
Feb-29-24 07:30AM	Neurogene to Participate in Upcoming Investor Conferences (Business Wire)
Jan-16-24 07:00AM	Neurogene Announces Appointment of Julie Jordan, M.D., as Chief Medical Officer (Business Wire) +7.27%
Jan-05-24 07:00AM	Neurogene Announces Business Update and 2024 Outlook (Business Wire) +6.50%
Dec-19-23 07:00AM	Neurogene Announces Closing of Merger with Neoleukin Therapeutics and Concurrent Private Placement of $95 Million (Business Wire) +8.17%

Neurogene, Inc. is a clinical-stage biotechnology company, which engages in the development of product portfolio of genetic medicines for rare neurological diseases. The company was founded in January 2018 and is headquartered in New York, NY.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

NGNE

Neurogene Inc

Upgrade your FINVIZ experience